Business context and reporting period
This is OncoCyte Corporation’s Form 10-K for the fiscal year ended December 31, 2019—not a quarterly report. The request metadata names Insight Molecular Diagnostics Inc., but the filing’s registrant is OncoCyte Corporation (NYSE American: OCX); investors should confirm the intended issuer.
OncoCyte was an early-stage molecular diagnostics company focused primarily on lung cancer. DetermaRx was its first commercially available test, while DetermaDx and DetermaIO remained in development. The company reported no revenue for either year presented. Its January 2020 acquisition of Insight Genetics, which added DetermaIO and pharmaceutical testing services, occurred after the reporting period and is not reflected in 2019 results.
Financial results and position
Amounts below are in millions of dollars except per-share data. The filing reports annual figures, not standalone fourth-quarter results.
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $6.8 | $6.5 |
| General and administrative expense | $13.3 | $7.0 |
| Sales and marketing expense | $2.2 | $1.7 |
| Total operating expenses / operating loss | $22.2 | $15.2 |
| Net loss | $22.4 | $15.8 |
| Basic and diluted net loss per share | $0.44 | $0.42 |
| Net cash used in operating activities | $19.7 | $11.6 |
- Operating expenses increased about 46%; net loss increased about 42%. G&A rose 89.5%, reflecting higher personnel and stock compensation, business-development and banking, legal and patent, and investor-relations costs.
- Cash and cash equivalents were $22.1 million at year-end 2019, versus $8.0 million a year earlier. The company also held $0.4 million in marketable equity securities. Cash-flow-statement cash, cash equivalents, and restricted cash totaled $23.8 million, including $1.7 million of restricted cash.
- Current assets were $23.0 million and current liabilities $4.4 million. Total liabilities were $9.0 million. The bank loan was $3.2 million principal, or $3.03 million net of deferred financing costs on the balance sheet; substantially all assets other than intellectual property secure the loan. Lease liabilities were also reported.
- Investing activities used $12.4 million, mainly the $11.245 million Razor investment and laboratory equipment. Financing activities provided $47.9 million, primarily from common-stock sales. No operating margin is meaningful because the company had no revenue.
- Accumulated deficit was $93.7 million. The company recorded no income-tax provision or benefit and maintained a full valuation allowance against deferred tax assets.
Material changes versus the prior period
- Net loss and operating cash use increased substantially as the company expanded corporate, commercial, and laboratory operations.
- Oncocyte invested $10 million in Razor for a 25% interest, plus related milestone and transaction costs, and obtained exclusive commercialization rights to DetermaRx. It raised $45.6 million net from stock sales during 2019 and refinanced its bank loan.
- The company ended its shared-services and facilities arrangement with former parent Lineage by December 31, 2019, shifting administrative and facility costs to its own operations.
- After year-end, Oncocyte raised approximately $7.6 million through a January 2020 stock offering, acquired Insight Genetics for cash and stock, and entered into a $25 million at-the-market equity sales agreement in March 2020.
Outlook, risks, contingencies, and unusual items
- Management said available cash, marketable securities, and access to the ATM facility were expected to fund current operations for at least 12 months from issuance of the financial statements. It also stated that further capital would be needed until test revenues cover operating expenses; financing may be unavailable or dilutive.
- Management expected a final CMS/MolDx coverage and pricing decision for DetermaRx in the first half of 2020. DetermaDx clinical validation was expected to finish by the end of the second quarter of 2020, with a possible second-half launch if results supported it. These are forward-looking statements, not reported outcomes.
- Key risks include clinical-validation results and launch delays, uncertain Medicare and private-payer coverage and reimbursement, physician adoption and competition, potential changes to LDT regulation, dependence on licensed intellectual property and specialized lab supplies, and limited capital. The filing also warned that COVID-19 could disrupt staff, reagent supply, CMS decisions, lung-cancer surgeries, marketing, and access to financing.
- Potential Razor obligations include a $4 million cash payment if final positive CMS coverage is received, up to $3 million in stock for clinical-trial enrollment, and additional trial costs; the company estimated its share of trial costs could reach $12 million. It also had an option, and under specified milestones an obligation, to buy remaining Razor shares for $10 million cash plus $5 million in stock, subject to terms and share limits.
- The Insight acquisition included up to $6 million of milestone consideration and revenue-sharing obligations. The filing reported no material litigation. The auditor gave an unqualified opinion on the financial statements; the auditor did not express an opinion on internal-control effectiveness.
Most important facts to verify
- Confirm the issuer and whether OncoCyte, rather than Insight Molecular Diagnostics Inc., is the intended company.
- Check actual CMS coverage and pricing decisions for DetermaRx and the subsequent reimbursement and collection history.
- Verify DetermaDx and DetermaIO validation, launch status, and commercial adoption against the timelines stated in this 2020 filing.
- Review subsequent cash burn, debt and lease commitments, equity issuance and dilution, and the terms or use of the ATM facility.
- Track Razor and Insight contingent payments, clinical-trial obligations, royalties, and any related changes to reported financial results.